Evaluating Urinary Biomarkers for Early Detection of Kidney Damage in Immune Checkpoint Inhibitors-Treated Patients.

ABSTRACT:

Introduction

Immune checkpoint inhibitors (ICIs) have improved cancer treatment; however, their use can be limited by immune-mediated adverse events, such as kidney damage. Diagnostic limitations of nephrotoxicity may lead to worsening of the patient's prognosis. This study aimed to validate a panel of urinary biomarkers as diagnostic tools for kidney damage in patients treated with ICIs.

Methods

A prospective study was conducted on patients scheduled to receive ICIs. Those who subsequently developed kidney damage were considered cases; and those who did not were considered controls. A battery of biomarkers was assessed in urine samples at PRE-1, before the first treatment cycle; PRE-3, before the third cycle; and POST-3, 1 week after the third treatment cycle.

Results

SUBMITTER: Casanova AG 

PROVIDER: S-EPMC12707895 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature